Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan
Risk-stratified treatment for EBV-HLH guided by DEX response and plasma EBV-DNA levels after 2 weeks of treatment was safe and effective.
Authors
- Kenichi Sakamoto (ORCID: https://orcid.org/0000-0003-1499-538X)
- Yozo Nakazawa (ORCID: https://orcid.org/0000-0003-0793-815X)
- Hirokazu Kanegane (ORCID: https://orcid.org/0000-0002-8696-9378)
- Ryu Yanagisawa (ORCID: https://orcid.org/0000-0003-4012-0958)
- Takehiko Doi (ORCID: https://orcid.org/0000-0003-0205-8663)
- Akiko Kada (ORCID: https://orcid.org/0000-0001-6350-5389)
- Tatsuya Negishi (ORCID: https://orcid.org/0000-0001-7266-2562)
- Akira Morimoto (ORCID: https://orcid.org/0000-0002-9168-5409)
- Akiko Saito (ORCID: https://orcid.org/0000-0003-3723-8445)
- Rintaro Ono (ORCID: https://orcid.org/0000-0001-8847-2528)
- Yoko Shioda
Institutions
- Children's Oncology Group (CH)
- Tokyo Medical and Dental University (JP)
- Shinshu University (JP)
- Fujita Health University (JP)
- St. Luke's International Hospital (JP)
- Hiroshima University Hospital (JP)
- Shinshu University Hospital (JP)
- National Center For Child Health and Development (JP)
- Nagoya Medical Center (JP)
- Showa Inan General Hospital (JP)
- Institute of Science Tokyo (JP)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1002/pbc.32166
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00